An Open Label, Single Center, Dose Escalation Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Single Ascending Dose of the Ebola Virus Vaccine rVSVΔG-ZEBOV-GP (BPSC1001)

Trial Profile

An Open Label, Single Center, Dose Escalation Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Single Ascending Dose of the Ebola Virus Vaccine rVSVΔG-ZEBOV-GP (BPSC1001)

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Mar 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top